Insulet Corp. (PODD) Stock: Price, Forecast & Analyst Target
Insulet Corp. (PODD) — MoonshotScore 85/100 (Exceptional band), calculated Nov 18, 2026. Price $139.98 (-3.69%), as of the Nov 18, 2026 trading session; market cap $9.71B. Expected results Feb 17, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 16.62× (cash as of Sep 30, 2026) · expected results Feb 17, 2027
Insulet Corp. · PODD · NASDAQ · Healthcare · Medical - Devices
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Insulet (PODD)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and elite growth, but a full valuation. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Quiet.
- quarterly revenue $706M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 8 of the last 8 reports
- expected results Feb 17, 2027
Helping: business quality, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 76 | Strong | |
| 76 | Strong | |
| 87 | Exceptional | |
| 87 | Exceptional | |
| 85 | Exceptional | |
| 85 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $139.98 | |
| Change on the day | -3.69% | |
| 52-week range | $126.40–$354.88 | |
| Market capitalisation | $9.71B | — |
| Price / earnings (trailing) | 23.63 | |
| Shares traded on the day | 2.09M | |
| Beta (volatility vs the S&P 500) | 1.06 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We expect the pace of innovation across the category to increase next year, including our launch of Omnipod 6.
Ashley A. McEvoy · Statement from
We have submitted the second and final 510(k) for Omnipod 6 and we will continue to expect launch in 2027. We believe we are better prepared for the Omnipod 6 launch than we have been for any launch in our history from customer targeting, and marketing to manufacturing, international expansion.
Ashley A. McEvoy · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Insulet (PODD): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Insulet (PODD), and what does it report?
Short answer
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. Insulet Corp. (PODD) is listed on NASDAQ. Healthcare / Medical Devices SEC filing business address: Acton, MA. It employs 5,400 people and is led by Ashley McEvoy. In Q3 FY2025 it reported revenue of $706M and net income of $88M. The market values it at $9.71B.
What do the latest results show for Insulet (PODD)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $706M. Against analyst estimates the company has EPS beat 8 of the last 8 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $842.00M Sep 30, 2026
- Latest quarter · R&D
- $91.60M Sep 30, 2026
- Latest quarter · SG&A
- $350.70M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $189.80M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $842.00M | $91.60M | $350.70M | $189.80M |
| Jun 30, 2026 | $801.70M | $88.10M | $344.80M | $129.70M |
| Mar 31, 2026 | $761.70M | $89.70M | $317.20M | $122.10M |
| Dec 31, 2025 | $783.80M | $90.90M | $331.40M | $146.30M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $842.00M Nov 4, 2026
- Latest report · revenue estimate
- $832.63M Nov 4, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 4, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 4, 2026 | $842.00M | $832.63M | $1.9900 | $1.5900 |
| Aug 5, 2026 | $801.70M | $787.39M | $1.6600 | $1.4700 |
| May 6, 2026 | $761.70M | $729.89M | $1.4200 | $1.1900 |
| Feb 18, 2026 | $783.80M | $768.97M | $1.5500 | $1.4700 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $706M | $88M | $1.24 (diluted) |
| Q4 FY2025 | $784M | $102M | $1.44 (diluted) |
| Q1 FY2026 | $762M | $91M | $1.30 (diluted) |
| Q2 FY2026 | $802M | $95M | $1.37 (diluted) |
What are the financial strengths and risks for Insulet (PODD)?
Short answer
Cash and short-term investments were $584.40M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $123.50M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway. The MoonshotScore pillars rate business quality, durable growth as strengths. The distress and quality screens read Altman Z 5.50 · Piotroski F 7. Trailing ratios: ROE 28.9% · ROA 11.4% · current ratio 2.51.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $123.50M Sep 30, 2026
- Previous quarter · operating cash flow
- $88.40M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $123.50M | −$57.10M |
| Jun 30, 2026 | $88.40M | −$29.00M |
| Mar 31, 2026 | $113.80M | −$27.80M |
| Dec 31, 2025 | $183.30M | −$135.10M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Insulet (PODD)?
Short answer · as of
The next earnings report is expected on Feb 17, 2027. Current published price targets run low $144.00 · high $235.00 · consensus $178.41 · median $175.00 against a quoted price of $139.98 (as of Nov 18, 2026).
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We completed enrollment in the EVOLVE pivotal study and we will continue to target a 510(k) submission in 2027 with a planned launch in 2028.
Ashley A. McEvoy ·
For The US, we now expect Omnipod revenue growth of 17.5% to 18.5% for the full year, which reflects year over year NCS growth positive pricing, and fourth quarter attrition and utilization remaining similar to Q3 levels.
Flavia H. Pease ·
What the records here don't tell us
- The newest quarter held here (Q3 FY2025) was filed Nov 6, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Insulet compare with its peers?
Short answer
Insulet's score ranks 6th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $70.53 Nov 18, 2026 | $9.34B | 94 5-pillar Nov 18, 2026 | |
| $82.52 Nov 18, 2026 | $30.8B | 93 5-pillar Nov 18, 2026 | |
| $404.02 Nov 18, 2026 | $28.1B | 92 5-pillar Nov 18, 2026 | |
| $320.50 Nov 18, 2026 | $12.6B | 92 5-pillar Nov 18, 2026 | |
| $94.54 Nov 18, 2026 | $5.21B | 88 5-pillar Nov 18, 2026 | |
| Insulet (PODD) — this page | $139.98 | $9.71B | 85 |
| $30.32 Nov 18, 2026 | $12.7B | 84 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $103.32 Nov 18, 2026 | $19.6B | 79 5-pillar Nov 18, 2026 | |
| $29.81 Nov 18, 2026 | $29.1B | 78 5-pillar Nov 18, 2026 | |
| $370.17 Nov 18, 2026 | $9.95B | 77 5-pillar Nov 18, 2026 | |
| $126.97 Nov 18, 2026 | $4.32B | 68 5-pillar Nov 18, 2026 | |
| $466.10 Nov 18, 2026 | $91.6B | 60 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $144.00 – $235.00
- Consensus target
- $178.41
- Median target
- $175.00
Consensus record · Captured .
Measured against a quoted price of $139.98 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 10
- Identified insiders
- 7
- Purchases
- 2
- Sales
- 1
- Other transactions
- 7
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 708 Period end Sep 30, 2026
- Previous quarter · holders
- 757 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 5,879,234 |
| Aqr Capital Management LLC | 4,748,776 |
| Sessa Capital Im, L.P. | 4,689,185 |
| Vanguard Capital Management LLC | 4,542,876 |
| Vanguard Portfolio Management LLC | 3,000,476 |
Tracked investors
Which of the 16 named investors we follow held PODD in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.05% | $10.82M | Trimmed −47.0% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Insulet (PODD)?
What Investors Ask About Insulet (PODD) — Healthcare
These answers are editorial: 1 of these 8 answers is drawn from the PODD research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for PODD?
PODD carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is PODD a good stock to buy?
Stock Expert AI does not rate PODD buy, sell or hold. Insulet Corp. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PODD stock price today?
The last price recorded for Insulet Corp. (PODD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the PODD price target?
The analyst consensus price target for Insulet Corp. (PODD), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for PODD?
The main risks for Insulet Corporation (PODD) include intense competition within the medical device industry from companies offering alternative insulin delivery systems or advanced diabetes management solutions, which could impact market share and pricing power.
What are the key factors to evaluate for PODD?
Insulet Corp. (PODD) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. This opportunity is ongoing and expected to persist for decades, fueling consistent demand for its products. Not financial advice.
How frequently does PODD data refresh on this page?
PODD's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PODD's recent stock price performance?
Insulet Corp. (PODD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary and differentiated tubeless insulin delivery technology (Omnipod System) offering enhanced user convenience and discretion. See the News tab for the latest drivers. Past performance does not predict future results.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 85 figures on this page — 2 from SEC filings and earnings calls, 74 from Financial Modeling Prep (FMP), 5 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
ETFs that hold PODD
Funds in our ETF coverage that list PODD among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| LGHT ETF | 7.01% | |
| The Obesity ETF (SLIM) | 6.27% |